A stability-indicating micellar electrokinetic capillary chromatography (MEKC) method was developed and validated for the analysis of doxorubicin hydrochloride in injectable pharmaceutical dosage forms, using methotrexate as internal standard. A fused-silica capillary (50 µm i.d.; effective length, 40 cm) and a running electrolyte solution consisting of 10 mM borate buffer and 20 mM anionic surfactant SDS, at pH 9.3, were set as the best experimental conditions. Moreover, the capillary temperature was maintained at 26 ºC, while the applied voltage was +26 kV. Hydrodynamic sample injection (6 s at 50 mbar) was used, and the detection was set at 260 nm using a photodiode array detector. The method was validated for the requirements specificity, linearity, precision, accuracy, and robustness, following the International Conference on Harmonisation (ICH) guidelines. The method linearity was proven in the range of 25-125 µg/mL (r = 0.9995). Forced degradation studies were successfully conducted, evidencing the specificity and stability-indicating capability of the method. In addition, no interference of the excipients from the formulation was detected. The values of accuracy and precision were within the acceptable limits, and robustness studies were performed by a two-level full factorial design. The proposed method fulfilled all validation parameters and was shown to be suitable for quantitative analyses of doxorubicin, contributing, thus, to the establishment of new alternatives with advantages for the quality control of pharmaceutical formulations.
Introduction
Doxorubicin (DOX), a member of the anthracycline ring antibiotics, is one of the considering first-line chemotherapeutic compounds, with suitable antitumor efficacy against a wide range of solid tumors. It is a hydrophilic drug, with mechanism of action consisting in binding to DNA by intercalation, with consequent induction of a series of biochemical events that lead to apoptosis in tumor cells (1, 2) . Cancer is one of the most common causes of death worldwide. Chemotherapy, although is considered the primary treatment for cancer among conventional modalities, displays many problems, such as low bioavailability, dose-limiting systemic toxicity and development of drug resistance (3) . Even so, the administration of chemotherapies grows along with the growing number of patients with cancer. Therefore, the analytical control is extremely important to ensure the quality of the pharmaceutical formulations available for the treatment of cancer.
Concerning analytical techniques available in the literature to determine DOX, the vast majority are about liquid chromatographic (LC) methods to quantify DOX in complexes biological matrices by fluorescence (4, 5) or UV detector (6) , as well as LC coupled to mass spectrometry (LC-MS) as a more sensitive methodology (7) . With regard to the drug analysis in pharmaceutical formulations, besides the available monographs in the main pharmacopoeias worldwide describing LC-UV methods, there is also a methodology described by Sastry and Rao (8) based on complexes colorimetric reactions and spectrophotometric measurements. LC is a powerful analytical technique; however, comprises important solvent consumption, which resulted in a large volume of liquid waste contaminated with antineoplastic drugs. Likewise, the spectrophotometry might not attend the acceptable standards of sensitivity and specificity depend on the drug and/or formulation matrix.
Capillary electrophoresis (CE) has appeared as a powerful analytical technique in the pharmaceutical area, with some advantages related to the existing analytical techniques (9) . As well as the LC, the CE is a closed system, which is particularly suitable in terms of safety for handling toxic samples. Moreover, it is characterized by a markedly low solvent consumption and a high versatility (10) . As one of the main disadvantages, is the low sensitivity attributed to the short optical path. However, for the analysis of drugs in pharmaceutical formulations, this is not a limitation, as solutions with enough concentrations can be prepared for the analysis. Some authors have reported capillary zone electrophoresis (CZE) or micellar electrokinetic capillary chromatography (MEKC) methods to quantify DOX especially in plasma samples. GAVENDA et al. (11) used CE method to determine two anthracyclines, doxorubicin and daunorubicin (DAU), by UV detection (190 -260 nm) using a fused-silica capillary with 50 μm i.d. and 45 cm effective length, 100 mM phosphate buffer pH 2.5 added 40% (v/v) methanol as background electrolyte and 150 mM SDS as a sweeping agent. The authors applied the method in samples of patient plasma. Moreover, CZE method was developed and validated in a curve range of 0.1 -100 μg/mL to analyze DOX and liposomal DOX (Myocet®) in plasma samples, using potassium phosphate buffer (12.5 mM, pH 7.4) and laser-induced fluorescence (LIF) detection (λex = 488 nm, λem = 630 nm) (12) . Lu et al. (13) developed and validated a microchip-based CE method with LIF detection (λex = 469 nm, λem = 518 nm) using 10 mM sodium tetraborate buffer at pH 8.5 with 40% acetonitrile to separate DOX and DAU. The method was linear in 1-75 μg/mL range and was applied to check the recovery ratio of these drugs in human serum sample. PÉREZ-RUIZ et al. (14) developed a CE method to separate the anthracyclines DOX, DAU and idarubicin in serum samples. The method used a fused-silica capillary 75 μm i.d. x 57 cm, 100 mM borate buffer pH 9.5 with 30% acetonitrile and appeared to be linear at 10-500 ng/mL range. MEKC was used to demonstrate the different metabolism between free and liposomal DOX (Doxil®) treating human leukemia cells. In this case, the buffer consisted of 20 mM γ-cyclodextrin, 50 mM borate and 50 mM SDS at pH 9.3, with LIF detection (λex = 488 nm, λem = 635 nm) (15) . In addition, a CE method was reported to assess DOX in pharmaceutical formulations; however, this method was focused in the analysis of multiple drugs in the same experimental procedure (10) . Sixteen antineoplastic drugs were determined and DOX was assessed by CZE with UV detection, using a 100 mM phosphate buffer at pH 2.5 containing 50% v/v of acetonitrile as background electrolyte, and dynamic coating of capillaries with Ceofix ® .
In view of these data, and considering that there is no published specific CE method for DOX determination in pharmaceutical formulations with UV detection, the objective of the present study was to develop and validate a stability-indicating MEKC method using UV-PDA detection, in accordance with ICH guidelines, as a tool to quantify DOX hydrochloride in injectable pharmaceutical dosage forms, with potential application in quality control analysis.
Experimental

Chemicals and reagents
Doxorubicin hydrochloride ( grade boric acid were acquired from Sigma-Aldrich (São Paulo, SP, Brazil) and Merck (Darmstadt, Germany), respectively. All chemicals used were of pharmaceutical or special analytical grade. For all analyses, ultrapure water was purified using a Mega RO/UP -Mega Purity system.
Apparatus
CE experiments were performed on an Agilent 7100 Capillary Electrophoresis system (Agilent Technologies, Waldbronn, Germany) equipped with an autosampler, a 1260 Infinity photodiode array (PDA) detector, a temperature controlling system (4-60 ºC) and power supply able to deliver up to 30 kV. A CE ChemStation software was used for instrument control, data acquisition and post run analysis of the electropherograms.
Solutions
Preparation of reference substance solutions
An exactly weighed amount of DOX was transferred to a volumetric flask and diluted to volume with ultrapure water, obtaining a reference solution with final concentration of 2 mg/mL. Methotrexate (MTX) solution, which was used as internal standard (IS), was prepared at a concentration of 1 mg/mL using dimethylsulfoxide (DMSO). These stock solutions were kept in refrigerator, protected from light, and daily diluted to an appropriate concentration (75 µg/mL for both DOX and IS) with running electrolyte solution.
Preparation of sample solutions
A proper amount of injectable pharmaceutical preparation containing 2 mg/mL of doxorubicin hydrochloride was accurately transferred to a volumetric flask and diluted to the concentration 75 µg/mL with running electrolyte solution. IS stock solution was also added to reach a final concentration of 75 µg/mL. This sample solution was filtered through a 0.22 µm membrane filter (Millipore) and then injected into the EC system.
Preparation of running electrolyte solution
The running electrolyte solution was prepared by dissolving separately boric acid and SDS, both equivalent to 100 mM, in ultrapure water and kept in refrigerator. Each day, the boric acid and SDS stock solutions were further diluted in order to obtain a solution with 10 and 20 mM, respectively. The pH was adjusted to 9.3 by adding 1 M sodium hydroxide (NaOH). This solution was filtered through a 0.22 μm.
Electrophoretic procedure
All experiments were carried out on a fused-silica capillary with 50 μm i.d. and 48.5 cm total length (effective length 40 cm, Agilent), maintained at 26°C and with detection wavelength set at 260 nm. The capillary was daily conditioned with 1 M NaOH, ultrapure water and then the running electrolyte solution, each for 20 minutes. Between runs, the capillary was sequentially washed with 0.1 M NaOH (180 s), ultrapure water (180 s) and running electrolyte solution (240 s). With this treatment method, it was possible to achieve reproducible measurements and enhance the capillary column lifetime. The samples were injected by hydrodynamic method (6 s at 50 mbar) and a constant voltage of +26 kV was applied during the analysis. After the last run of the experiments, the capillary was rinsed with 0.1 M sodium hydroxide, ultrapure water and finally dry cleaned.
Validation of the method
The method was validated using samples of injectable pharmaceutical formulation of doxorubicin hydrochloride with the label claim of 2 mg/mL by determinations of the following parameters: specificity, linearity, range, precision, accuracy, limit of detection (LD), limit of quantification (LQ), robustness, and system suitability test, following the International Conference on Harmonization (ICH) guidelines (16, 17) . Samples containing 75 µg/mL of both DOX and IS were used as work solutions during the validation process.
Forced degradation studies
The specificity and the stability-indicating capability of the method were evaluated by forced degradation studies in order to determine the potential interferences in the quantification of DOX. Solutions containing 1000 µg/mL of DOX were submitted to accelerated degradation in the following conditions: acidic and alkaline hydrolysis, heat, oxidant environment with hydrogen peroxide (H 2 O 2 ) and UVC radiation. A sample solution prepared in 0.1 M hydrochloric acid (HCl) was used for the acidic hydrolysis, and a sample solution in 0.01 M NaOH for the alkaline hydrolysis evaluation. These solutions were incubated at room temperature for 24 h and 30 min, respectively, and neutralized with base or acid, as necessary. To study the heat effect in the DOX degradation profile, the drug solution was diluted in water and heated in an incubator at 80 ºC for 24 h. The oxidative degradation was achieved by storing the solutions in 3% hydrogen peroxide, at room temperature for 24 h, protected from light. Photodegradation was induced by exposing the sample in a photostability chamber to UVC radiation for 24 h. The solutions were then diluted with the running electrolyte solution to a final DOX concentration of 75 µg/mL. The drug content after each degradation condition was measured and the purity of both DOX and IS peaks was verified using a PDA detector (peak purity index higher than 0.999 was considered acceptable).
Results and discussion
Optimization of the electrophoretic conditions
Optimization of the electrophoretic analysis was achieved by testing different methods based on CZE or MEKC separations. Initially, a CZE method was tested, investigating some electrolyte solutions containing sodium phosphate, boric acid, phosphoric acid or biological buffers such as TRIS and HEPES at different pH range (2.5 -10.0). Indeed, it is well know that the DOX pKa is about 8.2 (18) and, thus, it can be expected that at least 50% of the drug would be ionized at this tested pH range. Nevertheless, no appreciable results were achieved to proceed with the method validation in none of the tested conditions. As a conclusion of these preliminary experiments, we opted to investigate the MEKC method using the surfactant SDS and borate buffer, which provided superior detector response and better analysis time in the first tests by the CZE method. Different running conditions were tested, such as buffer strength, applied voltage, pH, as well as buffer additives. The borate buffer and SDS concentration studied ranged from 10 to 30 mM and 10 to 50 mM, respectively, combined or not with an organic modifier. The addition of an organic modifier to the buffer has been reported to improve selectivity in MEKC (19) . For this, we tested methanol or acetonitrile at small and different concentrations (5% -20%). Nevertheless, this option was excluded once these modifiers did not present any relevant improvements in the method optimization process. Different pH values for the running electrolyte solution were tested, ranging from 9.0 to 10.0, while the applied voltage was evaluated in the range 25 to 30 kV. From these studies, it was verified the gradually increase of the current as the buffer strength and voltage increases, as well as longer run times were obtained. Therefore, the use of 10 mM borate buffer at pH 9.3 and SDS 20 mM was considered the better condition for DOX analysis. It is noteworthy that similar buffers and pH range were used in studies mentioned elsewhere (13) (14) (15) . The samples were injected hydrodynamically at 50 mbar for 6 s and the voltage applied was set at +26 kV (current about 13 μA). A suitable separation performance was achieved within 8.0 min, with a DOX migration time of 4.3 min, showing also good peak area, intensity, symmetry and resolution. This condition showed a shorter migration time than the method developed by Pérez-Ruiz et al. (14) , in which DOX was detected at about 10 minutes, but longer than Lu et al. (13) , due to the use of a microchip by the authors. The best detection wavelength was set as 260 nm and, even though it is not one that correspond to the maximum absorption, was chosen due to the suitable sensitivity to both DOX and IS (Figure 1) , as well as lack of interferences from the formulation excipients (Figure 2) . The use of an IS is strongly recommended to compensate injection errors and minor fluctuations of the migration time during capillary electrophoresis analysis, thus improving the quantitative behavior. Then, some drugs, including nimesulide, furosemide and methotrexate, were tested, selecting methotrexate, another antitumor drug, which was found to be a suitable candidate, with a well resolved peak and good intensity. Figure 2 shows the typical electropherogram obtained with the optimized analytical conditions.
Validation of the method
The specificity of the method, which also determine the potential interference of the excipients of the pharmaceutical formulation, was evaluated by the analysis of placebo (an inhouse mixture of all excipients of the injectable solution without the active ingredient: sodium chloride, hydrochloric acid, sodium hydroxide and water for injection) (Figure 2) . Moreover, the specificity of the method towards the drug was established through determination of peak purity of the analyte and the IS, obtained by overlay of the spectra captured at the apex, upslope and downslope using a PDA detector. Peak purity index values higher than 0.9998 demonstrated that no formulation excipients were co-eluting with DOX, thus confirming that the proposed method is specific for the analysis of DOX in injectable pharmaceutical formulations.
A stability-indicating method is as an analytical procedure that accurately quantifies the active molecule without interference from process impurities, excipients and/or degradation products. Therefore, stress testing of the drug substance can aid the identification of the potential degradation products, as well as to develop and validate the stability-indicating power of an analytical procedure (20) . The forced degradation studies in neutral media followed by heat at 80ºC, as well as the photolytic condition, resulted in about 31 and 23% of drug degradation, respectively, with one eluting degradation product at the same migration time, of about 4 min (Figures 3a and b) . Under the alkaline hydrolysis, DOX content exhibited a significant decrease after just 30 min of exposition, and one additional resolved peak was detected at 3 min (Figure 3c ). In contrast, the acidic condition, only 12% of DOX degradation was observed after 24h and no additional peak was detected in the electropherogram (Figure 3d) , indicating that the degradation products did not migrate in the MEKC method or may have been degraded to nonchromophoric products. Finally, the oxidative condition also exhibited decrease of the area, with three additional peaks detected at about 3, 4 and 7.8 min (Figure 3e ). Table 1 shows the percentage of drug degradation for each stress condition. Peak purity analysis were also performed in all tested stress conditions, and acceptable values (> 0.9998) were obtained for both DOX and IS peaks. Linearity was determined by constructing three independent analytical curves in the range of 25-125 µg/mL prepared in running electrolyte solution. Three replicate injections of each reference solution spiked with MTX (75 µg/mL) as IS, were made to verify the repeatability of the detector response. The peak area ratio of DOX to the IS, against the respective reference concentrations, was used for plotting the graph, and the linearity evaluated by the least square regression analysis. The MEKC method was linear (r = 0.9995, y = 0.0142x + 0.0179, where x is concentration of DOX expressed in μg/mL and y is the peak area ratio of DOX to IS).
The LD and LQ were calculated by using the mean of the slope (S) and the standard deviation of the intercept (σ) of three independent analytical curves, determined by a linear regression model, as defined by ICH (16) . The theoretical values obtained were 4.60 and 15.32 μg/mL, for LD and LQ, respectively. Even though these parameters are not a requirement for drug assay, they are certainly important to evidence the method sensitivity.
The precision of the method was determined by repeatability (intra-day precision) and intermediate precision (inter-day and between-analysts precision), and the experimental results were expressed as relative standard deviation (RSD). Repeatability was examined by calculating the RSD of assay results (%) of six independent sample preparations at 75 µg/mL. The intermediate precision was assessed by analyzing three samples of the pharmaceutical formulation on two different days (inter-days) and by a second analyst (between-analysts). The precision results showed all RSD values lower than 2.0 %, as shown in Table 2 , demonstrating that the method variability was within the acceptable range. The accuracy was evaluated by the recovery of known amounts of reference solution, added to a sample solution, to obtain solutions at concentrations of 60, 75, and 90 μg/mL, equivalent to 80, 100, and 120%, of the analytical concentration (75 μg/mL), respectively. The accuracy was calculated at each concentration level from differences between the responses obtained for spiked and unspiked solutions. The absolute recovery values obtained for DOX are shown in Table 2 , with a satisfactory mean percentage of 100.76%, evidencing, thus, the accuracy of the method within the desired range.
The robustness was assessed by evaluating the capability of the method to remain unaffected by small, but deliberate, modifications in some of the methods settings. A two-level full factorial design (number of analyses equal to 2 k + n, where k is the number of factors and n is the number of central points) was performed using Minitab v.17 software (Minitab Inc., State College, PA, USA). Here, a 2 3 full factorial was applied, by analyzing samples after small changes in one, two or all of the following factors: borate buffer concentration in the electrolyte solution (8 and 12 mM), capillary temperature (24 and 28 ºC) and voltage applied (24 and 28 kV). Therefore, second-and third-order interactions were evaluated (21) . The analysis of the DOX reference and sample solutions containing 75 μg/mL were carried out in each combination, in a randomized order. The results were expressed as a Pareto chart (Figure 4 ), which shows that the single factors or their combinations did not significantly influence the analytical performance, since the bars did not cross the vertical line (critical t-value for α = 0.05). Moreover, there were non-significant changes of the migration time and peak area ratios, as well as of the electropherogram pattern, in comparison to the optimized conditions, indicating that the proposed method is robust under the conditions tested. A system suitability test was also carried out to evaluate the adequate performance and reproducibility of the system for the analysis to be executed, using six replicates injections of a reference substance solution containing 75 µg/mL of DOX and IS. The RSD values calculated for the migration time and peak area were 1.74 and 1.82%, respectively. The number of theoretical plates and peak symmetry were about 27597 and 1.03, with RSD of 1.65 and 1.05%, respectively. The resolution between DOX and IS peaks was 16.48, with RSD of 1.35%. Altogether, the experimental data showed that the parameters tested were within the acceptable range (RSD < 2.0%), indicating that the method is suitable for the analysis intended.
Method application
The validated MEKC method was applied for the determination of DOX in four different batches of an injectable pharmaceutical formulation. All batches showed mean content value in the range of 101.0 to 103.0%, with RSD lower than 1.0%. Therefore, the proposed method can be useful for the determination of DOX in injectable formulations, without prior separation of the excipients, with advantages of small sample volumes, short analysis time and no consumption of organic solvents, with the exception of a small amount of DMSO used to prepare the stock solution of the internal standard MTX.
Conclusion
The results of the validation studies show that the MEKC method is specific and stability-indicating. It possesses appropriate linearity, together with precision and accuracy within the acceptable limits. A full factorial design was successfully applied to assess robustness with many advantages over the traditional one-variable-at-time approach. The proposed method was also effectively applied for the quantitative analysis of doxorubicin in injectable pharmaceutical formulations, representing, thus, a simple and environment-friendly alternative for the quality control laboratory.
